KOSDAQBiotech & Pharma253840

Sugentech

₩4,530▼ 0.88%2026-10-02 close

Market Cap

₩77B

Turnover

₩500M

Volume

100,000 shares

Shares out.

16.7M

PER

—

PBR

1.0×

EPS

-₩1,504

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Amid Ongoing Losses, Mideast and Femtech Push for a Turnaround

Sugentech is restructuring around allergy diagnostics, femtech, and Middle East exports after the fade-out of its COVID-19 windfall, but profitability and balance-sheet strength remain weakened.

1
2025 revenue came to KRW 9.42 billion with an operating loss of KRW 18.82 billion, marking a third straight year of losses.
2
The 2025 net loss attributable to owners widened to KRW 23.31 billion from KRW 15.19 billion in 2024.
3
Over the last five quarters (2Q25-2Q26), revenue fluctuated between KRW 1.48 billion and KRW 3.17 billion without a clear recovery trend.
4
Total equity fell from KRW 140.58 billion in 2022 to KRW 76.54 billion in 2025, while the debt ratio rose from 23.3% to 28.3% over the same period.
5
The company is expanding into the Middle East and Europe centered on allergy diagnostics (S-Blot 3, SGTi-Allergy Screen) and its Surearly Smart female hormone digital healthcare platform.

Business structure

Sugentech is an in-vitro diagnostics (IVD) specialist founded in 2011 based on technology transferred from the Electronics and Telecommunications Research Institute (ETRI), listed on KONEX in 2016 and transferred to KOSDAQ in 2019.

Its core technology is a multiplex immunoblot platform combining BIO, NANO, IT and AI, complemented by point-of-care testing (POCT) products using TRF and fluorescence-based quantitative analysis.

Its main product lines include infectious disease diagnostic kits, allergy diagnostic reagents (SGTi-Allergy Screen), a fully automated immunoassay instrument (S-Blot 3), and the Surearly Smart female hormone digital healthcare platform.

During the COVID-19 pandemic, export sales of rapid antigen test kits drove results, but since the shift to an endemic phase the company has repositioned toward allergy diagnostics and femtech (women's health technology).

S-Blot 3 has obtained European CE-IVDR certification and also holds North American MDSAP certification, laying groundwork for entry into European and North American markets.

More recently, the company has built distribution networks in Middle East hub countries such as Saudi Arabia and the UAE, and showcased its allergy and point-of-care lineup at the WHX Labs Dubai 2026 exhibition.

Competitively, the market includes large global diagnostics firms as well as domestic peers such as LabGenomics and PrecisionBio, and Sugentech positions its multiplex immunoblot technology and certification portfolio as differentiators.

Its digital healthcare segment is anchored by Surearly Smart, which tests five female hormones, and the company is expanding into a health-and-beauty category as part of a broader wellness platform ambition.

Earnings trend

Quarterly revenue · Operating profit

₩3.2B-₩4.9B25Q2₩1.5B-₩4.8B25Q3₩2.9B-₩5.1B25Q4₩2.3B-₩4.7B26Q1₩3.1B-₩4.2B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩101.4B₩25B2022₩7.1B-₩22.8B2023₩10.1B-₩22B2024₩9.4B-₩18.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩3.2B	-₩4.9B	−154.1%
2025Q3	₩1.5B	-₩4.8B	−326.6%
2025Q4	₩2.9B	-₩5.1B	−178.1%
2026Q1	₩2.3B	-₩4.7B	−199.6%
2026Q2	₩3.1B	-₩4.2B	−137.0%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩101.4B	₩25B	₩26.7B	24.6%	19.0%	23.3%
2023	₩7.1B	-₩22.8B	-₩17.2B	−319.1%	−15.3%	18.4%
2024	₩10.1B	-₩22B	-₩15.2B	−218.1%	−15.6%	10.6%
2025	₩9.4B	-₩18.8B	-₩23.3B	−199.9%	−30.6%	28.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Sugentech's earnings contracted sharply after the COVID-19 windfall faded. Revenue peaked at KRW 101.40 billion with operating profit of KRW 24.97 billion in 2022, before plunging to KRW 7.13 billion in revenue in 2023, when the company swung to an operating loss of KRW 22.76 billion.

Revenue recovered modestly to KRW 10.10 billion in 2024, with the operating loss holding at a similar KRW 22.02 billion, and then revenue slipped again to KRW 9.42 billion in 2025 while the operating loss narrowed somewhat to KRW 18.82 billion.

However, the net loss attributable to owners widened from KRW 17.24 billion in 2023 and KRW 15.19 billion in 2024 to KRW 23.31 billion in 2025, diverging from the operating-loss improvement.

On a quarterly basis, revenue fell sharply from KRW 3.17 billion in 2Q25 to KRW 1.48 billion in 3Q25, before oscillating at KRW 2.87 billion in 4Q25, KRW 2.35 billion in 1Q26 and KRW 3.08 billion in 2Q26.

The operating loss stayed broadly in the KRW 4.2-5.1 billion range over the last five quarters, but the net loss attributable to owners spiked to KRW 11.18 billion in 4Q25, notably larger than the KRW 3.8-5.3 billion range seen in other quarters, suggesting a one-off item may have been booked.

Operating cash flow swung from an inflow of KRW 30.43 billion in 2022 to outflows of KRW 12.15 billion, KRW 7.52 billion, and KRW 14.65 billion in 2023, 2024, and 2025 respectively, three consecutive years of negative operating cash flow that underscores a persistently heavy fixed-cost burden relative to revenue scale.

Industry analysis

The global in-vitro diagnostics (IVD) market has seen its growth axis shift toward areas of recurring demand such as allergy, autoimmune, and molecular diagnostics as infectious-disease testing demand normalized after the fade-out of the COVID-19 pandemic windfall.

Many domestic IVD companies experienced sharp revenue declines and deteriorating earnings once the pandemic-driven boom ended, and Sugentech has not been an exception to this broader industry downcycle.

The allergy diagnostics market is viewed as having substantial underlying demand, with the World Health Organization classifying allergy among the major chronic diseases, and the company is positioning this segment along with femtech (women's health technology) as growth drivers.

The femtech market is reportedly expanding, centered on Silicon Valley in the United States, the United Kingdom, and India, while the competitive landscape in Korea remains at an early stage.

The Middle East and Africa region, which is heavily reliant on imported medical devices and where the relevant market has reportedly been expanding, has drawn attention as an emerging export destination for domestic diagnostics companies.

On the competitive front, large global diagnostics companies hold an advantage in capital and distribution networks, prompting smaller domestic IVD companies including Sugentech to pursue a strategy of targeting niche markets through certification acquisition and region-specific products.

Outlook

Since last year, the company has focused on expanding a high-value-added business model that combines allergy diagnostics and digital healthcare globally, building on distribution networks established in Middle East hub countries such as Saudi Arabia and the UAE.

At the WHX Labs Dubai 2026 exhibition held in Dubai, UAE in February 2026, the company said it showcased S-Blot 3, which has completed European CE-IVDR certification, the SGTi-Allergy Screen with country-specific panel design capability, and Surearly Smart, based on testing five female hormones, while reinforcing partnerships with partners in Europe and India.

The company had previously signed contracts worth a cumulative approximately KRW 14 billion with UAE- and Saudi Arabia-based companies, and the timing and scale at which this volume is actually recognized as revenue will be a key point to monitor going forward.

It is also reportedly pursuing a smart healthcare business partnership with China's Humanwell Healthcare Group, making the extent of Asian partnership expansion another item to watch.

New product launches in allergy diagnostics and femtech are cited as key variables for revenue growth, with the company pursuing a strategy of linking instrument and reagent sales to increase the recurring nature of overseas revenue.

However, the point at which this new-business expansion actually translates into improved profit and loss has not yet been confirmed through specific disclosed revenue guidance, and will need to be verified through upcoming quarterly results.

Valuation

PER

—

PBR

1.0×

ROE

-29.3%

EPS

-₩1,504

BPS

₩4,464

Dividend per share

₩0

Sugentech has seen its equity base continue to shrink amid accumulated net losses over recent years, leaving profit-based valuation metrics in a range where they cannot be meaningfully calculated.

The share price trades relatively close to the company's net asset value, suggesting the premium the market once assigned during the COVID-19 boom period has substantially narrowed.

No dividends have been paid through the most recent fiscal year, meaning there has been no track record of shareholder returns via dividends.

On the earnings side, while the scale of operating losses has shown a modestly improving trend, this has coincided with a widening net loss and shrinking equity base, meaning the market's future valuation assessment is likely to hinge on actual confirmation of revenue recovery and profit improvement.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Business Diversification Reshaping Revenue Sources

Since the end of the COVID boom, the company has been shifting its business axis toward allergy diagnostics, femtech, and digital healthcare. The company has stated that these areas are based on recurring demand and may therefore carry lower revenue volatility than infectious disease test kits.

Digital platforms such as Surearly Smart form part of a strategy to link instrument and reagent sales to increase the sustainability of overseas revenue.

Global Certifications and Emerging Market Distribution

S-Blot 3's European CE-IVDR certification and North American MDSAP certification lower regulatory barriers to entering overseas markets.

Distribution networks built in Middle East hub countries such as Saudi Arabia and the UAE, along with a cumulative contract worth approximately KRW 14 billion, could serve as a revenue base in emerging markets.

Pursuit of a partnership with China's Humanwell Healthcare Group also points to potential expansion of partnerships in Asia.

Gradual Narrowing of the Operating Loss

The annual operating loss narrowed modestly from KRW 22.76 billion in 2023 and KRW 22.02 billion in 2024 to KRW 18.82 billion in 2025.

The quarterly operating loss also showed a gradual narrowing trend, from KRW 4.89 billion in 2Q25 to KRW 4.23 billion in 2Q26, which can be interpreted as partly reflecting eased cost burdens and cost-reduction efforts.

Bear factors

Uncertainty Over Revenue Recovery

Annual revenue plunged from KRW 101.40 billion in 2022 to KRW 7.13 billion in 2023, and has remained at a low level of KRW 10.10 billion in 2024 and KRW 9.42 billion in 2025.

Revenue over the last five quarters has also merely oscillated between KRW 1.48 billion and KRW 3.17 billion without forming a clear upward trend. The timing at which new-business revenue will be substantially reflected remains unclear.

Widening Net Loss and Shrinking Capital

Unlike the improvement in operating loss, the net loss attributable to owners widened from KRW 15.19 billion in 2024 to KRW 23.31 billion in 2025. Total equity fell from KRW 140.58 billion in 2022 to KRW 76.54 billion in 2025, while the debt ratio over the same period rose from 23.3% to 28.3%.

The particularly large net loss of KRW 11.18 billion in 4Q25 is also a point that warrants further confirmation.

Persistently Negative Operating Cash Flow

Operating cash flow has been negative for three consecutive years from 2023 to 2025, at outflows of KRW 12.15 billion, KRW 7.52 billion, and KRW 14.65 billion respectively.

This suggests fixed-cost burdens remain heavy relative to revenue scale, and improvement in cash flow could be delayed if new-business revenue fails to expand.

Risk factors

Financial Structure

Total equity has continued to decline amid accumulated net losses, and the debt ratio is on an upward trend. Operating cash flow has been negative for three consecutive years, and if new-business revenue expansion is delayed, the need for additional external financing could arise.

Industry Competition

Demand for infectious disease test kits has fallen sharply since the shift to a COVID-19 endemic phase, and competition with large players in the global IVD market is intensifying.

New businesses in allergy diagnostics and femtech are also seeing entry from domestic and overseas competitors, making it uncertain whether differentiation can be sustained.

Regional and Counterparty Risk

The Middle East region has experienced ongoing geopolitical tensions recently, which could introduce variability in the timing and scale of export contract execution. Increased dependence on specific regions or counterparties could allow such risks to directly affect results.

What to watch next

Mid-November 2026
The 3Q26 quarterly report filing should be checked to see whether the recent revenue and profit/loss trend continues to improve.
4Q26 through early 2027
The timing and scale of revenue recognition for the unreflected portion of the roughly KRW 14 billion cumulative Middle East contracts should be confirmed through disclosures and IR communications.
Around March 2027
The 2026 annual business report (audited annual report) should be checked for confirmed figures on annual revenue, operating loss, equity, and debt ratio, as well as the audit opinion.
From 4Q26 onward
Follow-up disclosures should be checked to see whether the smart healthcare business partnership with China's Humanwell Healthcare Group progresses into a concrete contract or revenue.

Overall view

Sugentech has continued to post losses for three consecutive years since the fade-out of its COVID-19 windfall, while pursuing a business restructuring centered on allergy diagnostics, femtech, and Middle East exports.

The annual operating loss showed a modest narrowing trend between 2023 and 2025, but the net loss attributable to owners actually widened from KRW 15.19 billion in 2024 to KRW 23.31 billion in 2025, and total equity has declined for three consecutive years.

Operating cash flow has also been negative for three straight years, indicating that financial strength has been gradually weakening.

On the other hand, European CE-IVDR and North American MDSAP certifications, the establishment of a Middle East distribution network, and a cumulative contract of approximately KRW 14 billion provide a basis for diversifying overseas revenue.

Revenue and profit/loss over the most recent four quarters (3Q25-2Q26) have continued to fluctuate at low levels, meaning further confirmation through upcoming disclosures is needed to determine whether new businesses translate into actual revenue and profit improvement.

Overall, the company's strategic direction has become clearer, but time and additional confirmation are needed before the results are visibly reflected in the financial statements.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.